Skip to main content
. 2016 Jun 15;12:1744806916657088. doi: 10.1177/1744806916657088

Figure 1.

Figure 1.

Colitis-increased CGRP expression in L1 DRG was blocked by BDNF neutralization. TNBS treatment increased CGRP immunoreactivity in L1 DRG in the presence of normal IgG (A, B, and D). BDNF antibody treatment of colitis animals reduced CGRP immunoreactivity when compared to colitis (B, C, and D). TNBS treatment also increased CGRP mRNA levels examined by real-time PCR in L1 DRG in the presence of normal IgG (E). BDNF antibody treatment reduced CGRP mRNA level in colitis (E). Bar = 60 µm. *p < 0.05; **p < 0.01. n = 4–6 animals for each group.